Update and latest advances in antiretroviral therapy
L Menéndez-Arias, R Delgado - Trends in pharmacological sciences, 2022 - cell.com
Since the first cases of AIDS appeared in 1981, human immunodeficiency virus type 1 (HIV-
1) infection has reached pandemic proportions. Forty years later, research has led to the …
1) infection has reached pandemic proportions. Forty years later, research has led to the …
[HTML][HTML] Treatment emergent dolutegravir resistance mutations in individuals naive to HIV-1 integrase inhibitors: a rapid scoping review
K Tao, SY Rhee, C Chu, A Avalos, AK Ahluwalia… - Viruses, 2023 - mdpi.com
Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) rarely leads to
virological failure (VF) and drug resistance in integrase strand transfer inhibitor (INSTI)-naïve …
virological failure (VF) and drug resistance in integrase strand transfer inhibitor (INSTI)-naïve …
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel
Importance Recent advances in treatment and prevention of HIV warrant updated
recommendations to guide optimal practice. Objective Based on a critical evaluation of new …
recommendations to guide optimal practice. Objective Based on a critical evaluation of new …
First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an …
KA Christopoulos, J Grochowski… - Clinical Infectious …, 2023 - academic.oup.com
Background Long-acting injectable antiretroviral therapy (LAI-ART) is approved for treatment-
naive or experienced people with human immunodeficiency virus (HIV; PWH) based on …
naive or experienced people with human immunodeficiency virus (HIV; PWH) based on …
Expanded multivariable models to assist patient selection for long-acting cabotegravir+ rilpivirine treatment: clinical utility of a combination of patient, drug …
Background Previously reported post hoc multivariable analyses exploring predictors of
confirmed virologic failure (CVF) with cabotegravir+ rilpivirine long-acting (CAB+ RPV LA) …
confirmed virologic failure (CVF) with cabotegravir+ rilpivirine long-acting (CAB+ RPV LA) …
[HTML][HTML] Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
AG Cutrell, JM Schapiro, CF Perno, DR Kuritzkes… - Aids, 2021 - journals.lww.com
Objective: Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed
intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here …
intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here …
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Background There is a need for more convenient, less frequent treatment to help address
challenges associated with daily oral HIV treatment in people living with HIV, including …
challenges associated with daily oral HIV treatment in people living with HIV, including …
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase …
Background Previous work established non-inferiority of switching participants who were
virologically suppressed from daily oral standard of care to monthly long-acting …
virologically suppressed from daily oral standard of care to monthly long-acting …
[HTML][HTML] Infectious RNA: human immunodeficiency virus (HIV) biology, therapeutic intervention, and the quest for a vaccine
Y van Heuvel, S Schatz, JF Rosengarten, J Stitz - Toxins, 2022 - mdpi.com
Different mechanisms mediate the toxicity of RNA. Genomic retroviral mRNA hijacks infected
host cell factors to enable virus replication. The viral genomic RNA of the human …
host cell factors to enable virus replication. The viral genomic RNA of the human …
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult …
K Han, H Gevorkyan, J Sadik Shaik… - Antimicrobial Agents …, 2024 - Am Soc Microbiol
Cabotegravir+ rilpivirine administered via intramuscular gluteal injections is the first
complete long-acting (LA) regimen approved for maintaining HIV-1 virologic suppression …
complete long-acting (LA) regimen approved for maintaining HIV-1 virologic suppression …